elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. by combining expertise in materials science and immunology, elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. the elicio amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. this substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. elicio's lead amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. elicio was founded to expand and apply the ground-breaking amphiphile technology invented and developed in the labs of darrell
Company profile
Ticker
ELTX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Angion Biomedica Corp.
SEC CIK
Corporate docs
Subsidiaries
Elicio Operating Company, Inc. • Elicio Australia Pty Ltd. • Elicio Securities Corp. ...
ELTX stock data
Latest filings (excl ownership)
8-K
Other Events
5 Apr 24
S-8
Registration of securities for employees
29 Mar 24
S-3
Shelf registration
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Results of Operations and Financial Condition
29 Mar 24
D
$6.00 mm in options / securities to be acquired, sold $6.00 mm, 1 investor
28 Mar 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Other Events
17 Jan 24
8-K
Other Events
16 Jan 24
Latest ownership filings
SC 13D/A
Clal Biotechnology Industries Ltd.
10 Apr 24
SC 13D/A
Clal Biotechnology Industries Ltd.
20 Mar 24
SC 13D/A
GKCC, LLC
20 Mar 24
4
Yekaterina Chudnovsky
20 Mar 24
4
Brian Piekos
5 Feb 24
4
Robert Connelly
5 Feb 24
4
Christopher Haqq
5 Feb 24
4
Peter DeMuth
5 Feb 24
4
Allen Nissenson
29 Dec 23
4
Yekaterina Chudnovsky
29 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.20 mm | 17.20 mm | 17.20 mm | 17.20 mm | 17.20 mm | 17.20 mm |
Cash burn (monthly) | 1.72 mm | (no burn) | 3.59 mm | 3.75 mm | 1.73 mm | 3.86 mm |
Cash used (since last report) | 11.70 mm | n/a | 24.39 mm | 25.47 mm | 11.74 mm | 26.20 mm |
Cash remaining | 5.49 mm | n/a | -7.19 mm | -8.28 mm | 5.46 mm | -9.00 mm |
Runway (months of cash) | 3.2 | n/a | -2.0 | -2.2 | 3.2 | -2.3 |
Institutional ownership, Q3 2023
18.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 5 |
Closed positions | 0 |
Increased positions | 5 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 2.87 bn |
Total shares | 1.92 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GKCC | 702.64 k | $70.26 mm |
Clal Biotechnology Industries | 689.57 k | $6.49 mm |
Vifor | 199.56 k | $2.20 mm |
Vanguard | 140.53 k | $1.19 bn |
CM Management | 65.00 k | $549.25 mm |
Nantahala Capital Management | 30.00 k | $253.50 mm |
Geode Capital Management | 27.87 k | $235.60 mm |
Millennium Management | 20.38 k | $172.21 mm |
Citadel Advisors | 16.21 k | $136.94 mm |
Meyer Handelman | 13.90 k | $117.45 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Yekaterina Chudnovsky | Pre-Funded Common Stock Purchase Warrant Common Stock | Buy | Acquire P | Yes | No | 5.81 | 1,032,702 | 6.00 mm | 1,032,702 |
1 Feb 24 | Brian Piekos | Stock Option Common Stock | Grant | Acquire A | No | No | 4.5 | 43,225 | 194.51 k | 43,225 |
1 Feb 24 | Robert Connelly | Stock Option Common Stock | Grant | Acquire A | No | No | 4.5 | 225,137 | 1.01 mm | 225,137 |
1 Feb 24 | Christopher Haqq | Stock Option Common Stock | Grant | Acquire A | No | No | 4.5 | 28,200 | 126.90 k | 28,200 |
1 Feb 24 | Peter DeMuth | Stock Option Common Stock | Grant | Acquire A | No | No | 4.5 | 342 | 1.54 k | 342 |
1 Feb 24 | Peter DeMuth | Stock Option Common Stock | Grant | Acquire A | No | No | 4.5 | 29,800 | 134.10 k | 29,800 |
News
Elicio Therapeutics To Present Updated Clinical T Cell And Antigen Spreading Response Data From The Ongoing AMPLIFY-201 Phase 1 Study Of ELI-002 And Preclinical Data On ELI-007 And ELI-008 At The AACR Annual Meeting
5 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
5 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
18 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
8 Feb 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 Feb 24
Press releases
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
11 Apr 24
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
5 Apr 24
Unlocking the Power of Immunotherapy: Elicio Therapeutics' (NASDAQ: ELTX) Novel AMP Platform
5 Apr 24
Unlocking the Power of Immunotherapy: Elicio Therapeutics' (NASDAQ: ELTX) Novel AMP Platform
5 Apr 24
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
6 Feb 24